承担科研项目 5 项，发表论文 12 篇，其中SCI 6 篇，参编教材等 1 部。
[1]Wang H, Liao L, Xu Y, Long Y, Wang Y, Zhou Y. Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China. Front Oncol. 2022;12:1081750.
[2]Wang H, Liao L, Xu Y, Long Y, Wang Y, Zhou Y. Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China. Front Oncol. 2022;12:1081750.
[3]HaoWang,YeWang,RuixueGong,YuyuGeng,LiLi.Cost effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China[J].Ann Palliat Med. 2021 Nov;10(11):11382-11393.]
国家卫生健康委员会 《中国抗菌药物管理和细菌耐药现状报告》 中国协和医科大学出版社 2019科研项目：